Overall rank by patents
#6,143
Across all tracked assignees
USPTO PatentsView assignee record - 55 granted patents across 20 technology areas, active 2020–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61B (DIAGNOSIS; SURGERY; IDENTIFICATION).
The verdict
Exo holds 55 US patents across 20 technology areas, rank #6,143 of 50,000 tracked assignees.
Exo Imaging, Inc. has been granted 55 US utility patents between 2020 and 2025, placing Exo Imaging, Inc. at rank #6,143 across all assignees tracked by PlainPatent. This portfolio spans 20 distinct Cooperative Patent Classification (CPC) subclasses, averaging 23.4 claims per patent with primary concentration in A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). As a US Corporation, Exo Imaging, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Exo sits between East Carolina University (55 patents, rank #6,139) and Florida A&M University (55 patents, rank #6,147) - the closest US assignees by grant volume. The composite Innovation Score of 63.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2025, with 55 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Exo Imaging, Inc.'s 23.4 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while a multi-domain presence across 20 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Exo Imaging, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
East Carolina University
55 patents
Ellenberger & Poensgen GmbH
55 patents
Entellus Medical, Inc.
55 patents
Erasmus University Medical Center Rotterdam
55 patents
FLORICULTURA B.V.
55 patents
FMC Kongsberg Subsea AS
55 patents
FREEPORT MINERALS CORPORATION
55 patents
Florida A&M University
55 patents
Exo Imaging, Inc.
55 patents
What this shows Exo holds 55 patents at rank #6,143, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #6,143 in granted patent volume.
Other assignees with the most granted patents in Exo's primary technology class.
Exo's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
64 Top 2% higher than 98% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 3 | 5.5% |
| 2021 | 6 | 10.9% |
| 2022 | 3 | 5.5% |
| 2023 | 10 | 18.2% |
| 2024 | 22 | 40.0% |
| 2025 | 11 | 20.0% |
Top 15 of 20 technology areas
Overall rank by patents
#6,143
Across all tracked assignees
63.8 out of 100
How to use this portfolio
Exo's 55 grants land it in the top 2% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.